Loading…
Efficacy of prolonged valganciclovir therapy for congenital cytomegalovirus infection
Abstract We report prolonged valganciclovir (VGCV) treatment of a symptomatic cytomegalovirus infection case. Automated auditory brainstem evoked response performed at 5 days of age revealed severe hearing impairment. Cranial magnetic resonance (MR) imaging at 11 days of age showed abnormal findings...
Saved in:
| Published in: | Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy 2011, Vol.17 (4), p.538-540 |
|---|---|
| Main Authors: | , , , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c471t-afcb9324c148dc1b4a904e2ef7e10b925c9c9882e26b0e9a4262f5721957c7de3 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c471t-afcb9324c148dc1b4a904e2ef7e10b925c9c9882e26b0e9a4262f5721957c7de3 |
| container_end_page | 540 |
| container_issue | 4 |
| container_start_page | 538 |
| container_title | Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy |
| container_volume | 17 |
| creator | Kashiwagi, Yasuyo Kawashima, Hisashi Nakajima, Junya Ishida, Yu Nishimata, Shigeo Miyajima, Tasuku Takekuma, Kouji Hoshika, Akinori Inoue, Naoki |
| description | Abstract We report prolonged valganciclovir (VGCV) treatment of a symptomatic cytomegalovirus infection case. Automated auditory brainstem evoked response performed at 5 days of age revealed severe hearing impairment. Cranial magnetic resonance (MR) imaging at 11 days of age showed abnormal findings. At 5 weeks of age, VGCV was started. The viral load in blood cells, plasma, and urine decreased during the 6-week treatment. Because of improvement of hearing level and no adverse effects, VGCV was restarted for an additional 6 weeks. Neither the patient’s hearing impairment nor results of cranial MR imaging have become worse in 6 months. It is crucial to gather information from as many cases as possible treated with VGCV to establish a standard protocol for VGCV treatment. |
| doi_str_mv | 10.1007/s10156-010-0204-z |
| format | article |
| fullrecord | <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1007_s10156_010_0204_z</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S1341321X11704767</els_id><sourcerecordid>21229284</sourcerecordid><originalsourceid>FETCH-LOGICAL-c471t-afcb9324c148dc1b4a904e2ef7e10b925c9c9882e26b0e9a4262f5721957c7de3</originalsourceid><addsrcrecordid>eNp9kd1q3DAQRkVpadK0D9Cb4hdwOyPLK5tCoYSkLQRykQZyJ-TxaKvUay2Sd8F5-spxf6AXuZJA3xnxnRHiLcJ7BNAfEgLWmxIQSpCgyodn4hRVpUutG3ie75XCspJ4dyJepXQPgLpumpfiRKKUrWzUqbi9cM6TpbkIrtjHMIRxy31xtMPWjuRpCEcfi-kHR7ufCxdiQUti9JMdCpqnsOOtfQwdUuFHxzT5ML4WL5wdEr_5fZ6J28uL7-dfy6vrL9_OP1-VpDROpXXUtZVUhKrpCTtlW1As2WlG6FpZU0tt00iWmw64tUpupKu1xLbWpHuuzgSucymGlCI7s49-Z-NsEMyiyKyKTFZkFkXmITPvVmZ_6Hbc_yX-OMkBuQZSfspdo7kPhzjmHk9O_bhCnOsefYYSeR6Jex-zE9MH_yT96T-aBj_mvQw_eeb073-TpAFzsyx22SuiBqU3uvoFm8WcPg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Efficacy of prolonged valganciclovir therapy for congenital cytomegalovirus infection</title><source>Elsevier</source><creator>Kashiwagi, Yasuyo ; Kawashima, Hisashi ; Nakajima, Junya ; Ishida, Yu ; Nishimata, Shigeo ; Miyajima, Tasuku ; Takekuma, Kouji ; Hoshika, Akinori ; Inoue, Naoki</creator><creatorcontrib>Kashiwagi, Yasuyo ; Kawashima, Hisashi ; Nakajima, Junya ; Ishida, Yu ; Nishimata, Shigeo ; Miyajima, Tasuku ; Takekuma, Kouji ; Hoshika, Akinori ; Inoue, Naoki</creatorcontrib><description>Abstract We report prolonged valganciclovir (VGCV) treatment of a symptomatic cytomegalovirus infection case. Automated auditory brainstem evoked response performed at 5 days of age revealed severe hearing impairment. Cranial magnetic resonance (MR) imaging at 11 days of age showed abnormal findings. At 5 weeks of age, VGCV was started. The viral load in blood cells, plasma, and urine decreased during the 6-week treatment. Because of improvement of hearing level and no adverse effects, VGCV was restarted for an additional 6 weeks. Neither the patient’s hearing impairment nor results of cranial MR imaging have become worse in 6 months. It is crucial to gather information from as many cases as possible treated with VGCV to establish a standard protocol for VGCV treatment.</description><identifier>ISSN: 1341-321X</identifier><identifier>EISSN: 1437-7780</identifier><identifier>DOI: 10.1007/s10156-010-0204-z</identifier><identifier>PMID: 21229284</identifier><language>eng</language><publisher>Japan: Elsevier Ltd</publisher><subject>Antiviral Agents - administration & dosage ; Brain - diagnostic imaging ; Case Report ; Congenital infection ; Cytomegalovirus (CMV) ; Cytomegalovirus - genetics ; Cytomegalovirus - isolation & purification ; Cytomegalovirus Infections - congenital ; Cytomegalovirus Infections - diagnostic imaging ; Cytomegalovirus Infections - drug therapy ; Cytomegalovirus Infections - virology ; DNA, Viral - blood ; DNA, Viral - urine ; Evoked Potentials, Auditory, Brain Stem ; Ganciclovir - administration & dosage ; Ganciclovir - analogs & derivatives ; Hearing Loss - virology ; Hematology, Oncology and Palliative Medicine ; Humans ; Infant, Newborn ; Infant, Newborn, Diseases - diagnostic imaging ; Infant, Newborn, Diseases - drug therapy ; Infant, Newborn, Diseases - virology ; Infectious Diseases ; Magnetic resonance (MR) imaging ; Magnetic Resonance Imaging ; Male ; Medical Microbiology ; Medicine ; Medicine & Public Health ; Radiography ; Valganciclovir (VGCV) ; Viral Load ; Virology</subject><ispartof>Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, 2011, Vol.17 (4), p.538-540</ispartof><rights>Japanese Society of Chemotherapy and the Japanese Association for Infectious Diseases</rights><rights>2011 Japanese Society of Chemotherapy and the Japanese Association for Infectious Diseases</rights><rights>Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases 2011</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c471t-afcb9324c148dc1b4a904e2ef7e10b925c9c9882e26b0e9a4262f5721957c7de3</citedby><cites>FETCH-LOGICAL-c471t-afcb9324c148dc1b4a904e2ef7e10b925c9c9882e26b0e9a4262f5721957c7de3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21229284$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kashiwagi, Yasuyo</creatorcontrib><creatorcontrib>Kawashima, Hisashi</creatorcontrib><creatorcontrib>Nakajima, Junya</creatorcontrib><creatorcontrib>Ishida, Yu</creatorcontrib><creatorcontrib>Nishimata, Shigeo</creatorcontrib><creatorcontrib>Miyajima, Tasuku</creatorcontrib><creatorcontrib>Takekuma, Kouji</creatorcontrib><creatorcontrib>Hoshika, Akinori</creatorcontrib><creatorcontrib>Inoue, Naoki</creatorcontrib><title>Efficacy of prolonged valganciclovir therapy for congenital cytomegalovirus infection</title><title>Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy</title><addtitle>J Infect Chemother</addtitle><addtitle>J Infect Chemother</addtitle><description>Abstract We report prolonged valganciclovir (VGCV) treatment of a symptomatic cytomegalovirus infection case. Automated auditory brainstem evoked response performed at 5 days of age revealed severe hearing impairment. Cranial magnetic resonance (MR) imaging at 11 days of age showed abnormal findings. At 5 weeks of age, VGCV was started. The viral load in blood cells, plasma, and urine decreased during the 6-week treatment. Because of improvement of hearing level and no adverse effects, VGCV was restarted for an additional 6 weeks. Neither the patient’s hearing impairment nor results of cranial MR imaging have become worse in 6 months. It is crucial to gather information from as many cases as possible treated with VGCV to establish a standard protocol for VGCV treatment.</description><subject>Antiviral Agents - administration & dosage</subject><subject>Brain - diagnostic imaging</subject><subject>Case Report</subject><subject>Congenital infection</subject><subject>Cytomegalovirus (CMV)</subject><subject>Cytomegalovirus - genetics</subject><subject>Cytomegalovirus - isolation & purification</subject><subject>Cytomegalovirus Infections - congenital</subject><subject>Cytomegalovirus Infections - diagnostic imaging</subject><subject>Cytomegalovirus Infections - drug therapy</subject><subject>Cytomegalovirus Infections - virology</subject><subject>DNA, Viral - blood</subject><subject>DNA, Viral - urine</subject><subject>Evoked Potentials, Auditory, Brain Stem</subject><subject>Ganciclovir - administration & dosage</subject><subject>Ganciclovir - analogs & derivatives</subject><subject>Hearing Loss - virology</subject><subject>Hematology, Oncology and Palliative Medicine</subject><subject>Humans</subject><subject>Infant, Newborn</subject><subject>Infant, Newborn, Diseases - diagnostic imaging</subject><subject>Infant, Newborn, Diseases - drug therapy</subject><subject>Infant, Newborn, Diseases - virology</subject><subject>Infectious Diseases</subject><subject>Magnetic resonance (MR) imaging</subject><subject>Magnetic Resonance Imaging</subject><subject>Male</subject><subject>Medical Microbiology</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Radiography</subject><subject>Valganciclovir (VGCV)</subject><subject>Viral Load</subject><subject>Virology</subject><issn>1341-321X</issn><issn>1437-7780</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><recordid>eNp9kd1q3DAQRkVpadK0D9Cb4hdwOyPLK5tCoYSkLQRykQZyJ-TxaKvUay2Sd8F5-spxf6AXuZJA3xnxnRHiLcJ7BNAfEgLWmxIQSpCgyodn4hRVpUutG3ie75XCspJ4dyJepXQPgLpumpfiRKKUrWzUqbi9cM6TpbkIrtjHMIRxy31xtMPWjuRpCEcfi-kHR7ufCxdiQUti9JMdCpqnsOOtfQwdUuFHxzT5ML4WL5wdEr_5fZ6J28uL7-dfy6vrL9_OP1-VpDROpXXUtZVUhKrpCTtlW1As2WlG6FpZU0tt00iWmw64tUpupKu1xLbWpHuuzgSucymGlCI7s49-Z-NsEMyiyKyKTFZkFkXmITPvVmZ_6Hbc_yX-OMkBuQZSfspdo7kPhzjmHk9O_bhCnOsefYYSeR6Jex-zE9MH_yT96T-aBj_mvQw_eeb073-TpAFzsyx22SuiBqU3uvoFm8WcPg</recordid><startdate>2011</startdate><enddate>2011</enddate><creator>Kashiwagi, Yasuyo</creator><creator>Kawashima, Hisashi</creator><creator>Nakajima, Junya</creator><creator>Ishida, Yu</creator><creator>Nishimata, Shigeo</creator><creator>Miyajima, Tasuku</creator><creator>Takekuma, Kouji</creator><creator>Hoshika, Akinori</creator><creator>Inoue, Naoki</creator><general>Elsevier Ltd</general><general>Springer Japan</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>2011</creationdate><title>Efficacy of prolonged valganciclovir therapy for congenital cytomegalovirus infection</title><author>Kashiwagi, Yasuyo ; Kawashima, Hisashi ; Nakajima, Junya ; Ishida, Yu ; Nishimata, Shigeo ; Miyajima, Tasuku ; Takekuma, Kouji ; Hoshika, Akinori ; Inoue, Naoki</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c471t-afcb9324c148dc1b4a904e2ef7e10b925c9c9882e26b0e9a4262f5721957c7de3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Antiviral Agents - administration & dosage</topic><topic>Brain - diagnostic imaging</topic><topic>Case Report</topic><topic>Congenital infection</topic><topic>Cytomegalovirus (CMV)</topic><topic>Cytomegalovirus - genetics</topic><topic>Cytomegalovirus - isolation & purification</topic><topic>Cytomegalovirus Infections - congenital</topic><topic>Cytomegalovirus Infections - diagnostic imaging</topic><topic>Cytomegalovirus Infections - drug therapy</topic><topic>Cytomegalovirus Infections - virology</topic><topic>DNA, Viral - blood</topic><topic>DNA, Viral - urine</topic><topic>Evoked Potentials, Auditory, Brain Stem</topic><topic>Ganciclovir - administration & dosage</topic><topic>Ganciclovir - analogs & derivatives</topic><topic>Hearing Loss - virology</topic><topic>Hematology, Oncology and Palliative Medicine</topic><topic>Humans</topic><topic>Infant, Newborn</topic><topic>Infant, Newborn, Diseases - diagnostic imaging</topic><topic>Infant, Newborn, Diseases - drug therapy</topic><topic>Infant, Newborn, Diseases - virology</topic><topic>Infectious Diseases</topic><topic>Magnetic resonance (MR) imaging</topic><topic>Magnetic Resonance Imaging</topic><topic>Male</topic><topic>Medical Microbiology</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Radiography</topic><topic>Valganciclovir (VGCV)</topic><topic>Viral Load</topic><topic>Virology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kashiwagi, Yasuyo</creatorcontrib><creatorcontrib>Kawashima, Hisashi</creatorcontrib><creatorcontrib>Nakajima, Junya</creatorcontrib><creatorcontrib>Ishida, Yu</creatorcontrib><creatorcontrib>Nishimata, Shigeo</creatorcontrib><creatorcontrib>Miyajima, Tasuku</creatorcontrib><creatorcontrib>Takekuma, Kouji</creatorcontrib><creatorcontrib>Hoshika, Akinori</creatorcontrib><creatorcontrib>Inoue, Naoki</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kashiwagi, Yasuyo</au><au>Kawashima, Hisashi</au><au>Nakajima, Junya</au><au>Ishida, Yu</au><au>Nishimata, Shigeo</au><au>Miyajima, Tasuku</au><au>Takekuma, Kouji</au><au>Hoshika, Akinori</au><au>Inoue, Naoki</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Efficacy of prolonged valganciclovir therapy for congenital cytomegalovirus infection</atitle><jtitle>Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy</jtitle><stitle>J Infect Chemother</stitle><addtitle>J Infect Chemother</addtitle><date>2011</date><risdate>2011</risdate><volume>17</volume><issue>4</issue><spage>538</spage><epage>540</epage><pages>538-540</pages><issn>1341-321X</issn><eissn>1437-7780</eissn><abstract>Abstract We report prolonged valganciclovir (VGCV) treatment of a symptomatic cytomegalovirus infection case. Automated auditory brainstem evoked response performed at 5 days of age revealed severe hearing impairment. Cranial magnetic resonance (MR) imaging at 11 days of age showed abnormal findings. At 5 weeks of age, VGCV was started. The viral load in blood cells, plasma, and urine decreased during the 6-week treatment. Because of improvement of hearing level and no adverse effects, VGCV was restarted for an additional 6 weeks. Neither the patient’s hearing impairment nor results of cranial MR imaging have become worse in 6 months. It is crucial to gather information from as many cases as possible treated with VGCV to establish a standard protocol for VGCV treatment.</abstract><cop>Japan</cop><pub>Elsevier Ltd</pub><pmid>21229284</pmid><doi>10.1007/s10156-010-0204-z</doi><tpages>3</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1341-321X |
| ispartof | Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, 2011, Vol.17 (4), p.538-540 |
| issn | 1341-321X 1437-7780 |
| language | eng |
| recordid | cdi_crossref_primary_10_1007_s10156_010_0204_z |
| source | Elsevier |
| subjects | Antiviral Agents - administration & dosage Brain - diagnostic imaging Case Report Congenital infection Cytomegalovirus (CMV) Cytomegalovirus - genetics Cytomegalovirus - isolation & purification Cytomegalovirus Infections - congenital Cytomegalovirus Infections - diagnostic imaging Cytomegalovirus Infections - drug therapy Cytomegalovirus Infections - virology DNA, Viral - blood DNA, Viral - urine Evoked Potentials, Auditory, Brain Stem Ganciclovir - administration & dosage Ganciclovir - analogs & derivatives Hearing Loss - virology Hematology, Oncology and Palliative Medicine Humans Infant, Newborn Infant, Newborn, Diseases - diagnostic imaging Infant, Newborn, Diseases - drug therapy Infant, Newborn, Diseases - virology Infectious Diseases Magnetic resonance (MR) imaging Magnetic Resonance Imaging Male Medical Microbiology Medicine Medicine & Public Health Radiography Valganciclovir (VGCV) Viral Load Virology |
| title | Efficacy of prolonged valganciclovir therapy for congenital cytomegalovirus infection |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-23T20%3A09%3A31IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Efficacy%20of%20prolonged%20valganciclovir%20therapy%20for%20congenital%20cytomegalovirus%20infection&rft.jtitle=Journal%20of%20infection%20and%20chemotherapy%20:%20official%20journal%20of%20the%20Japan%20Society%20of%20Chemotherapy&rft.au=Kashiwagi,%20Yasuyo&rft.date=2011&rft.volume=17&rft.issue=4&rft.spage=538&rft.epage=540&rft.pages=538-540&rft.issn=1341-321X&rft.eissn=1437-7780&rft_id=info:doi/10.1007/s10156-010-0204-z&rft_dat=%3Cpubmed_cross%3E21229284%3C/pubmed_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c471t-afcb9324c148dc1b4a904e2ef7e10b925c9c9882e26b0e9a4262f5721957c7de3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/21229284&rfr_iscdi=true |